NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied ...
Zacks.com on MSN6d
APLT Stock Plunges 77% After FDA Issues CRL for Galactosemia Drug NDAApplied Therapeutics APLT announced that the FDA has issued a Complete Response Letter (CRL) for the new drug application ...
Applied Therapeutics said on Monday it received a warning letter limited to a trial studying its genetic disease drug, after ...
Applied Therapeutics (NASDAQ:APLT – Free Report) had its price objective lowered by Citigroup from $13.00 to $8.00 in a ...
Fintel on MSN1d
UBS Downgrades Applied Therapeutics (APLT)Fintel reports that on December 2, 2024, UBS downgraded their outlook for Applied Therapeutics (NasdaqGM:APLT) from Buy to ...
Applied Therapeutics faces challenges after FDA rejection, but future opportunities exist. Learn why APLT stock could recover ...
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...
Applied Therapeutics (NASDAQ:APLT – Free Report) had its price objective reduced by Robert W. Baird from $14.00 to $5.00 in a ...
Applied Therapeutics' New Drug Application for a rare metabolic disease was rejected by the Food and Drug Administration, ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...
Applied Therapeutics APLT announced that the FDA has issued a Complete Response Letter (CRL) for the new drug application (NDA) seeking approval for APLT’s lead candidate, govorestat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback